Blog
RSS FeedPosted by Michael Wonder on 10 Dec 2019
Pharmacare with no new medicines
10 December 2019 - Meeting with pricing officials shows that government's true goal is to slash prices so low that no ...
Posted by Michael Wonder on 07 Dec 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis
6 December 2019 - In May 2019 , Skyrizi received positive reimbursement recommendations from the Canadian Agency for Drugs and Technologies ...
Posted by Michael Wonder on 04 Dec 2019
B.C. wants federal health funding lift before national pharmacare program
3 December 2019 - B.C. wants more money from Ottawa for health care before a national pharmacare program is created, ...
Posted by Michael Wonder on 02 Dec 2019
Premiers want Ottawa to allow opt out for proposed Pharmacare plan
2 December 2019 - Canada's premiers say they want the federal government to increase health-care transfer funds by just over ...
Posted by Michael Wonder on 02 Dec 2019
Family asking for help to purchase 'the most expensive drug in the world'
1 December 2019 - Ricardo Batista is desperately hoping for a cure for SMA, for his daughter Eva. ...
Posted by Michael Wonder on 01 Dec 2019
The ‘Top 10’ challenges for health technology assessment: INAHTA viewpoint
28 November 2019 - The International Network of Agencies for Health Technology Assessment (INAHTA) spans the globe as a network of ...
Posted by Michael Wonder on 28 Nov 2019
Takhzyro (lanadelumab injection) receives positive recommendation from CADTH's Canadian Drug Expert Committee for the routine prevention of hereditary angioedema attacks
22 November 2019 - The positive recommendation is supported by the recently released findings of the Phase 3 Help Study™ Open-Label ...
Posted by Michael Wonder on 25 Nov 2019
Proposed Ontario drug regulation changes worry policy experts
22 November 2019 - The Ontario government is proposing drug regulation changes that it says will remove red tape and ...
Posted by Michael Wonder on 23 Nov 2019
Santen receives CADTH Canadian Drug Expert Committee reimbursement recommendation for Verkazia (cyclosporin 0.1%) eye drops
22 November 2019 - Santen Canada announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee ...
Posted by Michael Wonder on 22 Nov 2019
Revised process for cell and gene therapies
21 November 2019 - CADTH has undertaken an internal review and established a novel process for the review of cell and ...
Posted by Michael Wonder on 18 Nov 2019
Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that ...
Posted by Michael Wonder on 18 Nov 2019
Biosimilars make progress in the Canadian market, but stakeholders see more work ahead
18 November 2019 - While much attention over the past few weeks has been on the US biosimilars market, with its ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 18 Nov 2019
'This drug saved my life;' cystic fibrosis patient accuses drug company, Canada of stalling on approval
17 November 2019 - A West Island woman living with cystic fibrosis says the prohibitive price of a drug is ...
Posted by Michael Wonder on 29 Oct 2019
Costly prescription eye treatment highlights a loophole in Canada’s drug-price regulation process
28 October 2019 - The Ontario government has begun covering $100,000-a-year eye drops for an ultrarare disease, bringing relief to ...